Published studies on pulsed electromagnetic field (PEMF)

New Post Public Reply Private Reply Replies (0) Message Board
Bielionaire
214
Published studies on pulsed electromagnetic field (PEMF) therapy for osteoarthritis, including some that focus on the thumb carpometacarpal (CMC) joint and others with broader scope:

Systematic Reviews & Meta-Analyses

A 2020 meta-analysis found statistically significant improvements in pain, stiffness, and physical function with PEMF therapy compared to placebo. Pain reduction had a standardized mean difference (SMD) of 1.06, indicating a strong effect.

A 2024 systematic review of 17 randomized controlled trials (1,197 patients) reported a 60% decrease in pain and 42% improvement in WOMAC scores for knee osteoarthritis. Treatment durations ranged from 15 to 90 days.

Mechanism-Based Research

A 2025 study showed that PEMF therapy inhibits the NF-κB pathway and activates Sirt1, reducing inflammation and preserving cartilage in osteoarthritis models.

PEMF was found to increase chondrocyte proliferation and extracellular matrix production, which may help repair damaged cartilage3.

Thumb CMC Arthritis-Specific Insights

While direct published results for thumb CMC PEMF therapy are still pending (as in the Stanford trial), other studies suggest that manual therapy and therapeutic exercise can improve pain and function in this joint.

A randomized trial combining joint mobilization and neural mobilization showed better pain outcomes than sham treatment, though strength improvements were limited.

Comparative Trials

A 2023 randomized trial comparing PEMF to low-level laser therapy (LLLT) for knee OA found PEMF to be more effective in reducing pain during rest and activity, and improving functional scores like WOMAC and timed up-and-go tests.

ActiPatch® was used in several PEMF therapy studies, particularly those focused on musculoskeletal pain and osteoarthritis:

Knee Osteoarthritis

A double-blind, placebo-controlled trial published in Rheumatology (Oxford) tested a wearable PEMF device (ActiPatch) in 66 patients with knee OA.

Results showed significant reductions in pain (VAS score) and improved WOMAC scores.

26% of ActiPatch users discontinued NSAIDs or analgesics due to symptom relief.

Large-Scale Registry Study

BioElectronics Corporation conducted a 7-day trial program with over 44,000 users across the UK and Ireland.

Among 5,000 chronic pain sufferers who submitted assessments:

65% reported 57% average pain reduction

67% of opioid users reduced or eliminated medication

84% reported improved quality of life

93% confirmed long-term effectiveness

Plantar Fasciitis

A multicenter, double-blind trial showed overnight ActiPatch use significantly reduced heel pain.

Published in the Journal of Foot and Ankle Surgery.

Postoperative Pain

A Tufts University study evaluated ActiPatch for postoperative edema and pain after wisdom tooth extraction.

Though the trial was terminated early, it aimed to compare ActiPatch vs. placebo for swelling and pain relief.

ActiPatch has been actively studied and shows promising results across multiple conditions.

How does ActiPatch compare to other PEMF devices?
ActiPatch stands out among PEMF (Pulsed Electromagnetic Field) devices for its simplicity, affordability, and wearability, but it’s not the only player in the game. Here's how it stacks up against other popular PEMF options:

ActiPatch ($30–$50)

Type: Wearable, low-intensity PEMF device

Frequency: 1 kHz pulses at 27.12 MHz

Intensity: Very low (microtesla range)

Use Case: Chronic pain, arthritis, plantar fasciitis

Pros:

FDA-cleared for musculoskeletal pain

Affordable and easy to use

Long battery life (up to 720 hours)

Cons:

Limited intensity and depth of penetration

Disposable after battery life ends

FlexPulse ($500–$700)

Type: Localized PEMF device with multiple programs

Frequency Range: 0.5 Hz to 100 Hz

Intensity: Up to 300 Gauss

Pros:

Multiple frequency programs for different conditions

Rechargeable and portable

Stronger field for deeper tissue penetration

Cons:

Higher cost

Requires some setup and understanding of programs

Oska Pulse ($300–$400)

Type: Wearable PEMF device with a single automated program

Frequency: Varies through four healing stages

Intensity: ~9 Gauss

Pros:

Simple one-button operation

Targets inflammation, blood flow, pain, and healing

Medical device registration in multiple countries

Cons:

Lower intensity than FlexPulse

More expensive than ActiPatch

NeoRhythm ($300–$400)

Type: Head-worn PEMF device focused on neurological health

Use Case: Sleep, focus, meditation

Pros:

App-controlled with multiple brainwave programs

Innovative design for cognitive support

Cons:

Less suitable for musculoskeletal pain

Comfort issues during sleep

Bottom Line: ActiPatch is a great entry-level option for localized pain relief, especially if you're looking for something simple and budget-friendly. But if you need deeper tissue penetration, customizable programs, or neurological support, other devices like FlexPulse or NeoRhythm might be worth the investment.

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Yosvany Rodriguez Recognized for Excellence in Leadership

Updated Category News Views 98

Yosvany Rodriguez Celebrated for Leadership in Business Prominently featured as an influential leader, Yosvany Rodriguez is acknowledged for his exceptional contributions to strategic business leadership and innovation. His reputation is built on a solid foundation of experience and dedication, making him a respected figure in the business community. Key Contributions and...

Continue Reading
USA Rare Earth Faces Challenges with Magnet Demand Forecast

Updated Category News Views 236

Addressing Capacity Concerns in the Magnet Industry USA Rare Earth Inc. (NASDAQ: USAR) is currently grappling with significant challenges in meeting the increasing demand for magnets. Rob Steele, the CFO of the company, openly acknowledged these hurdles during a recent earnings call, emphasizing, "We don't have enough capacity to supply demand for 2026… our demand curve...

Continue Reading
Smartee and Shanghai Ninth People's Hospital Earn Prestigious Award

Updated Category News Views 222

Smartee and Shanghai Ninth People's Hospital Earn Title at Innovation Awards Smartee Denti-Technology, an innovative leader in orthodontic solutions, is thrilled to announce its recent achievement alongside Shanghai Ninth People's Hospital. Together, they have been awarded the First Prize at a notable scientific awards ceremony, highlighting their collaboration in...

Continue Reading
Asian Stock Markets React to Rate Cuts and Retail Troubles

Updated Category News Views 80

Overview of Recent Asian Stock Market Trends Recently, stock markets across Asia have shown a generally positive trend, driven by optimism surrounding lower interest rates announced by several central banks. However, the Australian markets have faced a decline, primarily due to substantial losses reported by key retailers dealing with legal challenges. Investors are...

Continue Reading
ibex Contributes $25,000 to Support Wounded Veterans

Updated Category News Views 155

ibex's Generous Contribution to Veterans' Welfare ibex (NASDAQ: IBEX), a prominent global provider of business process outsourcing (BPO) and AI-driven customer engagement solutions, is elated to announce a donation of $25,000 to the Wounded Warrior Project (WWP) under its philanthropic initiative, ibex Cares. This support is a crucial contribution to WWP’s mission,...

Continue Reading